View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 3, 2017

M&As this week: Hildred Capital Partners, Novartis, Neos Therapeutics

Private investment firm Hildred Capital Partners plans to acquire a majority stake in pharmaceutical company Crown Laboratories.

By Rosanna Jeffery

Private investment firm Hildred Capital Partners plans to acquire a majority stake in pharmaceutical company Crown Laboratories.

Both companies involved in the transaction are based in the US.

Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.

Novartis is a pharmaceutical company based in Switzerland, while AAA is a French radiopharmaceutical company.

Neos Therapeutics, Inc. (formerly Neostx Inc.) has rejected PDL BioPharma’s plans to acquire its entire outstanding shares for $10.25 a share.

“Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.”

Both pharmaceutical companies involved in the transaction are based in the US.

Alembic Pharmaceuticals has acquired generic drug developer Orit Laboratories.

The acquisition enables the Indian pharmaceutical company to expand its footprint in the US.

US-based biotechnology company Amgen plans to acquire the remaining 50% stake in Kirin-Amgen, a joint venture (JV) between integrated beverage company Kirin Holdings and Amgen.

The JV will pay $780m to Kirin and consequently become a wholly owned subsidiary of Amgen.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology